Loading…
Alector, Inc. is projected to rise to $1.96 by 2027, a +30% move from its current price of $1.51. ALEC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.45 | $1.51 | $1.57 | +0.09% |
| Aug 5 | $1.43 | $1.51 | $1.60 | +0.19% |
| Aug 6 | $1.41 | $1.51 | $1.63 | +0.28% |
| Aug 7 | $1.40 | $1.52 | $1.65 | +0.37% |
| Aug 8 | $1.38 | $1.52 | $1.66 | +0.46% |
| Aug 9 | $1.37 | $1.52 | $1.68 | +0.56% |
| Aug 10 | $1.36 | $1.52 | $1.69 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.36 | $1.52 | $1.69 | +0.65% |
| Week 2 | $1.31 | $1.53 | $1.78 | +1.31% |
| Week 3 | $1.28 | $1.54 | $1.86 | +1.97% |
| Week 4 | $1.25 | $1.55 | $1.93 | +2.63% |
| Week 5 | $1.22 | $1.56 | $1.99 | +3.30% |
| Week 6 | $1.20 | $1.57 | $2.05 | +3.97% |
| Week 7 | $1.19 | $1.58 | $2.11 | +4.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alector, Inc. is a clinical stage biotechnology company that develops therapies to counteract the progression of neurodegeneration in the United States.
Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart.
The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC is the stock symbol for Alector, Inc. The asset trades at $1.62 with a market cap of $179.86M and a rank of 3641. The current price and market position place it within the healthcare sector as a biotechnology name focused on neurodegeneration therapies.
The 30-day technical picture and near-term path show a defined trading range and key levels, while the forecast outlines a multi-year upside. The forecast spans from 2026 through 2050, with year-by-year Avg prices and max ranges that illustrate a strong longer-term bullish bias despite near-term volatility.
A major floor 35.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
The nearest ceiling, 37.7% above — a clean break opens room to run.
A major ceiling 79.1% above — clearing it would confirm fresh momentum.
Key ALEC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALEC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.54 | Sell | $1.54 | Sell |
| MA 10 | $1.51 | Sell | $1.54 | Sell |
| MA 20 | $1.57 | Sell | $1.58 | Sell |
| MA 50 | $1.75 | Sell | $1.74 | Sell |
| MA 100 | $2.03 | Sell | $1.87 | Sell |
| MA 200 | $1.88 | Sell | $1.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.84 | Neutral |
| Stoch RSI (14) | 67.38 | Neutral |
| CCI (20) | -37.46 | Neutral |
| Williams %R (14) | -47.83 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 0.67 | Buy |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 52.17 | Neutral |
| TRIX (15) | -0.74 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 47.04 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 1.56 | Sell |
| ADX (14) | 18.98 | Neutral |
| ATR (14) | 0.06 | Info |
Near-term sentiment is NEUTRAL with RSI14 at 50. The stock trades with SMA50 at $1.76 and SMA200 at $1.89, suggesting price motion around these moving averages.
Support is reported at $1.39 and resistance at $2.08, framing a near-term trading zone. The 30-day price range sits between $1.25 and $2.11, highlighting a relatively wide short-term swing and ongoing volatility as indicated by an annualized volatility of 80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.39 | $1.51 | $2.15 | 0% | Neutral | |
| $1.49 | $1.96 | $2.76 | +30% | Bullish | |
| $1.74 | $2.38 | $3.54 | +58% | Bullish | |
| $1.58 | $2.25 | $3.49 | +49% | Bullish | |
| $1.55 | $2.29 | $3.66 | +52% | Bullish | |
| $1.52 | $2.31 | $3.80 | +53% | Bullish | |
| $1.32 | $2.07 | $3.49 | +37% | Bullish | |
| $1.69 | $2.73 | $4.71 | +80% | Bullish | |
| $2.00 | $3.31 | $5.85 | +119% | Bullish | |
| $1.90 | $3.22 | $5.80 | +113% | Bullish | |
| $2.07 | $3.96 | $7.74 | +162% | Bullish | |
| $3.40 | $7.55 | $16.57 | +400% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.39 | $1.51 | $1.83 | +0.00% |
| September 2026 | $1.26 | $1.52 | $1.89 | +0.38% |
| October 2026 | $1.36 | $1.64 | $2.08 | +8.41% |
| November 2026 | $1.39 | $1.70 | $2.18 | +3.65% |
| December 2026 | $1.34 | $1.66 | $2.15 | -2.67% |
Click any year to see its month-by-month ALEC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ALEC is projected to trade between $1.39 and $2.15, averaging $1.51 — a potential gain of 0% from today's $1.51. Price action looks broadly range-bound.
Alector, Inc.'s 2027 outlook centres on $1.96, within a $1.49 to $2.76 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ALEC could reach as high as $3.54, with a base case around $2.38 and support toward $1.74 — roughly +58% from $1.51. Momentum favours further upside here.
Expect ALEC to range from $1.58 to $3.49 through 2029. The $2.25 average target implies a +49% move from current prices. That is -5% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The ALEC price prediction for 2030 points to an average of $2.29 (low $1.55, high $3.66) — a potential gain of +52% on today's $1.51. Momentum favours further upside here.
In 2031, ALEC is projected to trade between $1.52 and $3.80, averaging $2.31 — a potential gain of +53% from today's $1.51. That is up +1% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Alector, Inc.'s 2032 outlook centres on $2.07, within a $1.32 to $3.49 range. That is -10% versus the projected 2031 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2033, ALEC could reach as high as $4.71, with a base case around $2.73 and support toward $1.69 — roughly +80% from $1.51. Buyers look set to stay in control over this stretch.
Expect ALEC to range from $2.00 to $5.85 through 2034. The $3.31 average target implies a +119% move from current prices. That is up +22% on the projected 2033 average. Momentum favours further upside here.
The ALEC price prediction for 2035 points to an average of $3.22 (low $1.90, high $5.80) — a potential gain of +113% on today's $1.51. Buyers look set to stay in control over this stretch.
In 2040, ALEC is projected to trade between $2.07 and $7.74, averaging $3.96 — a potential gain of +162% from today's $1.51. That is up +23% on the projected 2035 average. Momentum favours further upside here.
Alector, Inc.'s 2050 outlook centres on $7.55, within a $3.40 to $16.57 range. That is up +91% on the projected 2040 average. That marks a +400% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALEC today (≈ 662.251656 ALEC) could be worth
$5,001.98
+$4,001.98 (+400%) by 2050 · US Dollar
Based on the average projected ALEC price of $7.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALECwould be worth at today's price.
$1,000 invested in ALEC on Jul 31, 2025 (≈ 671.140935 ALEC) would be worth
$1,013.42
+$13.42 (+1.3%) today · 1.01× · US Dollar
Based on a ALEC entry price of $1.49 vs. today's $1.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.48 | $1,020.27 | +2.0% |
| 1 month ago | $2.01 | $751.24 | -24.9% |
| 3 months ago | $2.36 | $639.83 | -36.0% |
| 6 months ago | $1.99 | $758.79 | -24.1% |
| 1 year ago | $1.49 | $1,013.42 | +1.3% |
| All time (5.0y) ago | $27.74 | $54.43 | -94.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALEC forecast.
Our base-case forecast reaches $3.00 around 2034.
Implied market cap at $3.00: $333.08M
The multi-year forecast shows a clear bullish tilt after 2026, with the average price rising from $1.62 in 2026 to higher levels in subsequent years. The 2027 avg is $2.13 (max $2.98) with a 31.3% ROI and bullish sentiment, followed by 2028 avg $2.57 (max $3.79) and 58.4% ROI. The trajectory continues with 2029 avg $2.44 (max $3.75) and 50.7% ROI, then 2030 avg $2.50 (max $3.97) and 54.3% ROI, and 2031 avg $2.53 (max $4.13) with 56% ROI.
By 2032 the avg sits at $2.30 (max $3.86) with 42.3% ROI, and 2033 returns an avg of $3.08 (max $5.27) with 90% ROI. The expansion accelerates in 2034, where the avg reaches $3.70 (max $6.46) and 128.1% ROI, followed by 2035 at $3.58 (max $6.38) and 120.9% ROI. The forecast projects continued upside into the 2040s, with 2040 avg $4.54 (max $8.77) and 180.5% ROI, culminating in 2050 avg $8.59 (max $18.58) and 430.3% ROI with bullish sentiment.
These figures imply meaningful upside across the long horizon, driven by ongoing development activity and strategic collaborations. However, these are estimates, not guarantees, and actual results will depend on a range of factors including scientific progress, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast lists min $1.71, avg $2.50, max $3.97 with ROI 54.3 and sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages, reaching avg $8.59 by 2050 and ROI 430.3 by 2050, though near-term figures can be flat (e.g., 2026 avg $1.62, ROI 0). These are estimates, not guarantees.
Yes. The 2033 max is $5.27 and the 2034 max is $6.46, indicating it could surpass $5 in the forecast horizon.
Current price is $1.62 and market cap is $179.86M, with a rank of 3641.
The 30-day range is $1.25 to $2.11, with a near-term support at $1.39 and resistance at $2.08.
Alector, Inc. Community Discussion
0Share your Alector, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.